Monday, October 03, 2011

21: days of protection left for Lilly's Zyprexa | The Indianapolis Star |

Still, no one on Wall Street is expecting Lilly to collapse. Some analysts say Lilly is on the right track and could bounce back in a few years. Lilly stock has remained in the mid- to high 30s for most of the past two years, although that's down from the 50s four years ago.

"It's going to be a challenge for Lilly, but survivability is not a question," said Linda Bannister, a drug analyst at Edward Jones and Co. in St. Louis, who has a "hold" rating on the stock. "They have some interesting things in the pipeline, and if they are successful, Lilly could be a growth company again."

The company has about 70 experimental drugs under development. They include about 10 in late-stage clinical testing for serious ailments such as Alzheimer's disease (a medicine called solanezumab), depression (NERI), cancer (ramucirumab), schizophrenia (mGlu2/3 pro) and diabetes (BI 10773).

It's been more than a decade since Lilly went through such a financial upheaval. In 2001, the company found itself in a crisis when it suddenly lost patent exclusivity on Prozac, its best-selling antidepressant, which accounted for 34 percent of the company's sales.

Posted via email from Jack's posterous

1 comment:

Daniel Haszard said...

Lilly did make their money on Zyprexa around $41 billion so far and they still expect to capture 20% of the US market as well as a billion year on ZyprexaXR.
The patent only expires in the US and some Euro,Lilly announced they have an *authorized* distributor of generic Zyprexa hmmmm.
The litigations on the Viva Zyprexa scandal are mostly dried up except for one omnipresent claimant.
--- Daniel Haszard Zyprexa victim activist and patient who got diabetes from it.